Product Information

BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $0.6379 per EA under NDC 00054018913. Its NADAC has been published 628 times since Aug 13, 2014.

FDA first approved this application on Jun 27, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET

buprenorphine hydrochloride and naloxone hydrochloride dihydrate
$0.6379per EA
DEA Schedule CIII

Strength

8; 2 mg/1; mg/1

NDC

00054018913

Classification

Generic

Dosage Form

TABLET

Route

SUBLINGUAL

Effective Date

8/19/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA203326

FDA Approved

6/27/2014

TE Code

AB

On Market Since

6/27/2014

Pharmacological Classes

Opioid Antagonist
Opioid Antagonists
Partial Opioid Agonist
Partial Opioid Agonists

Price Statistics

The NADAC for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET has been published 628 times since Aug 13, 2014, and over the history we have for it it has declined 89.7%. The table below summarizes its recorded NADAC range and movement.

Current price$0.6379 per EA
All-time high$6.1950 (Aug 13, 2014)
All-time low$0.6322 (Jul 22, 2026)
52-week high$0.7333
52-week low$0.6322
Median price$1.3203
Average price$2.2615
Largest weekly change+29.6% (Aug 21, 2024)
Weeks tracked628
Tracking sinceAug 13, 2014

Price History

1W

+0.9%

1M

+0.9%

3M

-5.9%

6M

-6.3%

1Y

-13.0%

3Y

-38.5%

5Y

-40.4%

All

-89.7%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET?

The current National Average Drug Acquisition Cost (NADAC) for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET, manufactured by Hikma Pharmaceuticals USA Inc., is $0.6379 per EA (NDC 00054018913), effective Aug 19, 2026.

How has the price of BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET changed over time?

Over the history we have for it, the NADAC for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET has declined 89.7%. It has been tracked across 628 weekly CMS publications since Aug 13, 2014.

What are the highest and lowest recorded NADAC prices for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET?

Since Aug 13, 2014, the NADAC for BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET has ranged from a low of $0.6322 (Jul 22, 2026) to a high of $6.1950 (Aug 13, 2014), with a median of $1.3203 per EA.

Are there cheaper alternatives to BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET?

1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET in a comparable dosage form, but none are currently priced below it.

Who manufactures BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET?

BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET (NDC 00054018913) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.